Atumnus, Inc. — the institutional entity that founds the discipline and stewards its canonical reference.
Co-founder and Chief Executive Officer of Atumnus, Inc. Daniel William Dorsey leads the institutional, commercial, and partnership strategy of the founding entity, with primary responsibility for the patent portfolio, licensing relationships, and the institutional reference at endogenicpharmacology.com. His prior work spans health-and-longevity product development, regulatory navigation, and the commercial translation of biomedical research.
Co-founder and Chief Technology Officer of Atumnus, Inc. Daniel Nowak leads the scientific, technical, and infrastructure architecture of the founding entity, with primary responsibility for the bioregulator composition portfolio, the formulation technology base, and the operational systems that support the discipline's clinical and commercial translation. His background spans full-stack engineering, autonomous and assistive AI systems, and the integrated infrastructure that ties scientific, clinical, and commercial operations into a coherent institutional program.
“Endogenic pharmacology is the natural extension of the pharmaceutical sciences into the next century of medicine. Where the first century mastered exogenous intervention, the next will master endogenous regulation. We are honored to found this discipline and to provide the canonical framework for its growth.”